



FOR IMMEDIATE RELEASE

Contacts:

For Ohmx Corporation:

Jodi Soriano
Tel: (847) 491-8500
jodi@ohmxbio.com

For Osmetech:

Geoffrey A. McKinley, PHD
VP R&D and Business Development
Osmetech Molecular Diagnostics
136 Weymouth Street
Rockland, MA 02370
Email: geoff.mckinley@osmetech.com
Phone: 770 510 4444 ext 7108

Edward Kreusser, Esq.
VP Intellectual Property and Legal Affairs
Osmetech Molecular Diagnostics
757 South Raymond Street
Pasadena, CA 91105
Email: ed.kreusser@osmetech.com
Phone: 626 463 2000 ext 8017

Osmetech licenses self-assembling monolayer (SAM) technology to Evanston, Illinois-based Ohm_x Corporation

October 16, 2006 – Osmetech plc (AIM; LSE) today announced that it has signed a non-exclusive commercial license with Evanston, Illinois-based Ohm_x Corporation to Osmetech's self-assembling monolayer (SAM) technology for biosensor use. Ohm_x's current agreement with Osmetech is just the latest in a series of deals between Osmetech and Ohm_x. Ohm_x's founder and Chairman of the Board, Thomas Meade, Ph.D. also co-founded Clinical Micro Sensors and is an inventor on many of the California Institute of Technology's (Cal Tech) and Clinical Micro Sensors' (CMS) patents held or exclusively licensed by Osmetech. Financial details were not disclosed.

Osmetech, a fast developing, international diagnostics business with operations in Atlanta, Boston and Pasadena, USA serves the high growth, near patient molecular testing market and holds exclusive rights to the SAM technology. The SAM technology, invented by George Whitesides, Ph.D. at Harvard University, is finding increasing merit, particularly in electrochemistry-based biosensing methodologies, where it is used to minimize background signal, provide for uniform functionalized attachment of molecules and to reduce nonspecific aggregation events.

James White, CEO of Osmetech, said, "When Osmetech acquired CMS from Motorola, it came with a patent portfolio that had over \$25 million spent on it and over 80 granted patents. Today marks an important step in our ability to maximize our economic return by looking to actively license our portfolio to companies in complementary product areas and also for non-healthcare diagnostic markets such as research, forensics, environmental, biodefense and food. We look forward to announcing other partnerships in the near future."

“The SAM patents are just one complementary piece of a much broader intellectual property position held by Osmetech in the field of electrochemistry-based detection”, says Edward Kreusser, Osmetech’s VP of Intellectual Property and Legal Affairs. “In addition to the Harvard SAM IP, Osmetech also holds exclusive rights to very valuable biosensing patents owned by Cal Tech, University of North Carolina, CMS and Concordia University”.

About Osmetech, Inc

(www.osmetech.com)

Osmetech plc is an AIM-listed public company on the London Stock Exchange. The company is a fast developing, international diagnostics business with operations in Atlanta, Boston and Pasadena in the US, serving the high growth, near patient testing market targeting small to medium sized hospitals. Osmetech operates in two business areas, namely Molecular Diagnostics and Critical Care Diagnostics. Osmetech has launched eSensor®, an FDA cleared electrochemistry-based array system for cystic fibrosis carrier detection and plans to launch a number of pharmacogenomic assays utilizing the same proprietary technology.

About Ohm_x Corporation

(www.ohmxbio.com)

Ohm_x Corporation is a protein biosensor company focused on the development of portable, electronic detection devices for use in *in vitro* diagnostics and other applications such as biodefense, food safety and water testing. The Company’s technology was invented by Dr. Thomas Meade, previous founder and co-founder of two successful biotech companies. Dr. Meade’s revolutionary research yielded a new, simple and easy way to electronically detect a wide variety of targets such as bacteria, viruses and mold. Ohm_x began operations in January 2005, to provide immediate and accurate detection results. Further information is available on Ohm_x’s website: www.ohmxbio.com